Mirostipen

Drug Profile

Mirostipen

Alternative Names: HG 00300; HGO 0300; MPIF 1; Myeloid progenitor inhibitory factor 1

Latest Information Update: 17 Apr 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Human Genome Sciences
  • Class Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myelosuppression

Most Recent Events

  • 17 Apr 2002 Discontinued - Phase-II for Myelosuppression in USA (Infusion)
  • 14 Jun 2000 A phase I study has been added to the adverse events section
  • 20 Nov 1998 Phase-II clinical trials for Myelosuppression in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top